The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Phosphodiesterase 4 (PDE4) inhibitors are immunomodulatory drugs approved to treat diseases associated with chronic inflammatory conditions, such as COPD, psoriasis and atopic dermatitis. Tanimilast (international non-proprietary name of CHF6001) is a novel, potent and selective inhaled PDE4 inhibit...

Full description

Bibliographic Details
Main Authors: Hoang Oanh Nguyen, Tiziana Schioppa, Laura Tiberio, Fabrizio Facchinetti, Gino Villetti, Maurizio Civelli, Annalisa Del Prete, Francesca Sozio, Carolina Gaudenzi, Mauro Passari, Ilaria Barbazza, Silvano Sozzani, Valentina Salvi, Daniela Bosisio
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Immunology
Subjects:
COVID-19
proinflammatory cytokines
cDCs
pDCs
phosphodiesterase 4 (PDE4) inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.797390/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.797390/full

Similar Items